Insight into 2019 novel coronavirus - An updated interim review and lessons from SARS-CoV and MERS-CoV

Mingxuan Xie, Qiong Chen, Mingxuan Xie, Qiong Chen

Abstract

Background: The rapid spread of the coronavirus disease 2019 (COVID-19), caused by a zoonotic beta-coronavirus entitled 2019 novel coronavirus (2019-nCoV), has become a global threat. Awareness of the biological features of 2019-nCoV should be updated in time and needs to be comprehensively summarized to help optimize control measures and make therapeutic decisions.

Methods: Based on recently published literature, official documents and selected up-to-date preprint studies, we reviewed the virology and origin, epidemiology, clinical manifestations, pathology and treatment of 2019-nCoV infection, in comparison with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) infection.

Results: The genome of 2019-nCoV partially resembled SARS-CoV and MERS-CoV, and indicated a bat origin. The COVID-19 generally had a high reproductive number, a long incubation period, a short serial interval and a low case fatality rate (much higher in patients with comorbidities) than SARS and MERS. Clinical presentation and pathology of COVID-19 greatly resembled SARS and MERS, with less upper respiratory and gastrointestinal symptoms, and more exudative lesions in post-mortems. Potential treatments included remdesivir, chloroquine, tocilizumab, convalescent plasma and vaccine immunization (when possible).

Conclusion: The initial experience from the current pandemic and lessons from the previous two pandemics can help improve future preparedness plans and combat disease progression.

Keywords: 2019- nCoV; COVID-19; MERS- CoV; SARS-CoV; SARS-CoV- 2.

Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.

References

    1. Assiri A., Al-Tawfiq J.A., Al- Rabeeah A.A., Al-Rabiah F.A., Al-Hajjar S., Al-Barrak A. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013;13:752–761. doi: 10.1016/S1473-3099(13)70204-4.
    1. Backer J.A., Klinkenberg D., Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020. Euro Surveill. 2020:25.
    1. Badawi A., Ryoo S.G. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129–133. doi: 10.1016/j.ijid.2016.06.015.
    1. Bauch C.T., Lloyd-Smith J.O., Coffee M.P., Galvani A.P. Dynamically modeling SARS and other newly emerging respiratory illnesses: past, present, and future. Epidemiology. 2005;16:791–801. doi: 10.1097/01.ede.0000181633.80269.4c.
    1. Bauch C.T., Oraby T. Assessing the pandemic potential of MERS-CoV. Lancet. 2013;382:662–664.
    1. Chan J.F., Kok K.H., Zhu Z., Chu H., To K.K., Yuan S. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020;9:221–236. doi: 10.1080/22221751.2020.1719902.
    1. Chen J., Ling Y., Xi X.H., Liu P., Li F., Li T. Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia. Chin J Epidemiol. 2020;38 doi: 10.3760/cma.j.cn311365-20200210-00050. Epub E008.
    1. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.
    1. Chen Q., Wang L., Xie M., Li X. Recommendations for influenza and Streptococcus pneumoniae vaccination in elderly people in China. Aging Med. 2020;0:1–11. doi: 10.1002/agm2.12102.
    1. Coutard B., Valle C., de Lamballerie X., Canard B., Seidah N.G., Decroly E. The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade. Antiviral Res. 2020;176 doi: 10.1016/j.antiviral.2020.104742.
    1. Cowling B.J., Park M., Fang V.J., Wu P., Leung G.M., Wu J.T. Preliminary epidemiological assessment of MERS-CoV outbreak in South Korea, May to June 2015. Euro Surveill. 2015;20:7–13. doi: 10.2807/1560-7917.es2015.20.25.21163.
    1. Gao J., Tian Z., Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047.
    1. Gorbalenya A.E., Baker S.C., Baric R.S., RJd Groot, Drosten C., Gulyaeva A.A. 2020. Severe acute respiratory syndrome-related coronavirus—The species and its viruses, a statement of the Coronavirus Study Group.
    1. Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 doi: 10.1056/NEJMoa2002032. [accessed 28 Feb 2020]. In press.
    1. Hoffmann M., Kleine-Weber H., Schroeder S., Kruger N., Herrler T., Erichsen S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically-proven protease inhibitor. Cell. 2020;181(2):271–280.e8. doi: 10.1016/j.cell.2020.02.052.
    1. Holshue M.L., DeBolt C., Lindquist S., Lofy K.H., Wiesman J., Bruce H. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020;382(10):929–936. doi: 10.1056/NEJMoa2001191.
    1. Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.
    1. Jaillon S., Berthenet K., Garlanda C. Sexual dimorphism in innate immunity. Clin Rev Allergy Immunol. 2019;56:308–321. doi: 10.1007/s12016-017-8648-x.
    1. Ji W., Wang W., Zhao X., Zai J., Li X. Cross-species transmission of the newly identified coronavirus 2019- nCoV. J Med Virol. 2020;92:433–440. doi: 10.1002/jmv.25682.
    1. Lam T.T., Shum M.H., Zhu H.C. 2020. Identification of 2019-nCoV related coronaviruses in Malayan pangolins in southern China.
    1. Le R.Q., Li L., Yuan W., Shord S.S., Nie L., Habtemariam B.A. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23:943–947.
    1. Lessler J., Reich N.G., Brookmeyer R., Perl T.M., Nelson K.E., Cummings D.A. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009;9:291–300.
    1. Li Q., Guan X., Wu P., Wang X., Zhou L., Tong Y. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 doi: 10.1056/NEJMoa2001316.
    1. Lipsitch M., Cohen T., Cooper B., Robins J.M., Ma S., James L. Transmission dynamics and control of severe acute respiratory syndrome. Science. 2003;300:1966–1970. doi: 10.1126/science.1086616.
    1. Liu Y., Gayle A.A., Wilder-Smith A., Rocklov J. The reproductive number of COVID-19 is higher compared to SARS coronavirus. J Travel Med. 2020;27(2):1–4. doi: 10.1093/jtm/taaa021.
    1. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565–574. doi: 10.1016/S0140-6736(20)30251-8.
    1. Mair-Jenkins J., Saavedra- Campos M., Baillie J.K., Cleary P., Khaw F.M., Lim W.S. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015;211:80–90. doi: 10.1093/infdis/jiu396.
    1. Mulangu S., Dodd L.E., Davey R.T., Jr., Tshiani Mbaya O., Proschan M., Mukadi D. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019;381:2293–2303. doi: 10.1056/NEJMoa1910993.
    1. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med. 2003;348:1322–1332. doi: 10.1056/NEJMoa025028.
    1. Nicholls J.M., Poon L.L., Lee K.C., Ng W.F., Lai S.T., Leung C.Y. Lung pathology of fatal severe acute respiratory syndrome. Lancet. 2003;361:1773–1778. doi: 10.1016/s0140-6736(03)13413-7.
    1. Nishiura H., Linton N.M., Akhmetzhanov A.R. Serial interval of novel coronavirus (2019-nCoV) infections. MedRxiv(preprint) 2020 doi: 10.1101/2020.02.03.20019497. Submitted for publication.
    1. Park J.E., Jung S., Kim A., Park J.E. MERS transmission and risk factors: a systematic review. BMC Public Health. 2018;18:574. doi: 10.1186/s12889-018-5484-8.
    1. Pei F., Zheng J., Gao Z.F., Zhong Y.F., Fang W.G., Gong E.C. Lung pathology and pathogenesis of severe acute respiratory syndrome: a report of six full autopsies. Clin J Pathol. 2005;34:656–660.
    1. Qian I., Rongshuai W., Guoqiang Q., Yunyun W., Pan L., Yingzhi Z. A report on the general observation of a 2019 novel coronavirus autopsy. J Forensic Sci. 2020;36:1–3. doi: 10.12116/j.issn.1004-5619.2020.01.00.
    1. Sheahan T.P., Sims A.C., Leist S.R., Schafer A., Won J., Brown A.J. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11:222. doi: 10.1038/s41467-019-13940-6.
    1. Sui J., Li W., Murakami A., Tamin A., Matthews L.J., Wong S.K. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc Natl Acad Sci U S A. 2004;101:2536–2541. doi: 10.1073/pnas.0307140101.
    1. van Griensven J.F., Edwards T., de Lamballerie X., Semple M.G., Gallian P., Baize S. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. N Engl J Med. 2016;374:33–42. doi: 10.1056/NEJMoa1511812.
    1. Vincent M.J., Bergeron E., Benjannet S., Erickson B.R., Rollin P.E., Ksiazek T.G. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005;2:69. doi: 10.1186/1743-422X-2-69.
    1. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020 doi: 10.1001/jama.2020.1585. In press.
    1. Wang M., Cao R., Zhang L., Yang X., Liu J., Xu M. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. WHO . 2020. Summary of probable SARS cases with onset of illness from 1 November 2002 to 31 July 2003.
    1. WHO . 2020. WHO MERS Global Summary and Assessment of Risk.
    1. WHO . 2020. Novel Coronavirus(2019-nCoV) Situation Report-51 2020.
    1. Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020;367(6483):1260–1263. doi: 10.1126/science.abb2507.
    1. Wu A., Peng Y., Huang B., Ding X., Wang X., Niu P. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe. 2020;27(3):325–328. doi: 10.1016/j.chom.2020.02.001.
    1. Wu Z., McGoogan J.M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) Outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020 doi: 10.1001/jama.2020.2648. In press.
    1. Xu X., Chen P., Wang J., Feng J., Zhou H., Li X. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63(3):457–460. doi: 10.1007/s11427-020-1637-5.
    1. Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422. doi: 10.1016/S2213-2600(20)30076-X.
    1. Yang Y., Liu M.J., Wang Y.X., Zhang A.R., Jalali Neda, Dean Natalie. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. MedRxiv. 2020 doi: 10.1101/2020.02.10.20021675. Submitted for publication.
    1. Yu W.B., Tang G.D., Zhang L., Corlett R.T. Decoding the evolution and transmissions of the novel pneumonia coronavirus (SARS-CoV-2) using whole genomic data. ChinaXiv. 2020 doi: 10.12074/202002.00033. Submitted for publication.
    1. Zhao Yu, Wang Y.J., Zhou Y.Q., Ma Y., Zuo Y. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. BioRxiv(preprint) 2020
    1. Zhu N., Zhang D., Wang W., Li X., Yang B., Song J. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382:727–733. doi: 10.1056/NEJMoa2001017.
    1. Zumla A., Hui D.S., Azhar E.I., Memish Z.A., Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 doi: 10.1016/S0140-6736(20)30305-6.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner